Ear drug delivery to get a boost from launch of hearing loss therapeutics company Decibel

VC firm Third Rock is funding (to the tune of $52 million) and assembling a team focused on fighting hearing loss with drugs, an effort that's sure to push the envelope when it comes to drug delivery and administration within the ear. Decibel Therapeutic's founders include Charles Liberman of Harvard Medical School, who studies the use of neurotrophins to restore synapses. The company promises to "combine recent innovations in hearing science with leading diagnostic tools, biological insights, modeling and therapeutic delivery techniques." GlaxoSmithKline's ($GSK) venture arm also participated in the Series A round. More from FierceBiotech

Suggested Articles

Xeris bucked pandemic trends with the July launch of its Gvoke HypoPen for hypoglycemia, boosting glucagon prescriptions across the board.

Chiasma's new acromegaly pill Mycapssa, aiming to convert patients from injectables, turned out positive 48-week data from an extension study.

Medicated chewing gum is a prime drug delivery target, but it's tough to test. An experimental set of robot jaws could ease that burden.